Amarin Corp Plc (AMRN)

[ziploc_1]

HDG...QUOTE..." I am not aware of the full details of the Hikma case, so could not say or deny it is the "same" or different situation but I am sure an "explicit" promotion by Hikma should be exist to win the case."

This turns on what is meant by "explicit"...Hikma bragged in 2020 in a public a meeting of financial analysts that.... "Company forecasts sales as high as $700m after regulator grants broad label."

This figure could not be realistically achieved by selling gV solely for Rx for the high triglyceride indication, which is only 7% of the Vascepa market...It is a very "explicit' statement of Hikma's intention to infringe on Vascepa's CVD indications, which are 93% of the market.

This evidence was introduced at the Amarin vs. Hikma and Healthnet trial. and was convincing enough for magitrate judge Hall to find for Amarin.